Epitalon: how it got to PCAC

Origin

Epitalon, also written Epithalon or Epithalone, is a synthetic tetrapeptide of sequence Ala-Glu-Asp-Gly (AEDG). The 2025 review by Araj and colleagues at the Medical University of Warsaw described the molecule as a short peptide derived from the amino-acid composition of Epithalamin, an extract of bovine pineal gland that the St Petersburg Institute of Bioregulation and Gerontology characterized in the 1980s and 1990s PMID 40141333. The early Russian literature outlining that family of “short bioregulator” peptides — including AEDG — was summarized in Khavinson’s 2002 monograph supplement in Neuro Endocrinol Lett PMID 12374906.

Research history

The cited literature is dominated by laboratory and animal work. Araj et al. (2025) summarized roughly twenty-five years of investigations reporting that Epitalon influences melatonin synthesis, modulates interleukin-2 messenger RNA, affects telomerase enzyme activity, and produces antioxidant and antimutagenic signals in cell-culture and rodent models. The same authors noted that physicochemical and structural characterization of the tetrapeptide is comparatively thin, and observed that

It remains uncertain whether these are the sole mechanisms of action of this compound.

Independent peer-reviewed human-trial data are scarce in the indexed literature, and the bulk of the published clinical reports originate from a small number of laboratories.

Regulatory journey

Epitalon has no FDA-approved indication and no marketing authorization in any major jurisdiction reviewed by the cited sources. Under section 503A of the Federal Food, Drug, and Cosmetic Act, FDA maintains a list of bulk drug substances that may be used by traditional compounders even when those substances are not the subject of an approved drug application. The agency’s program page describes the nomination process and the interim three-category framework: Category 1 substances are eligible for compounding pending final rulemaking; Category 2 substances raise significant safety concerns and are not eligible pending further review; Category 3 substances were nominated without enough information to evaluate (FDA — Bulk Drug Substances Used in Compounding).

A range of peptide nominations, including Epitalon-related substances, were placed in Category 2 pending advisory-committee review under FDA’s “may present significant safety risks” notice (FDA Category 2 notice).

FDA scheduled Epitalon for the Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 (FDA advisory-committee calendar). PCAC’s role is to advise the agency on whether a nominated substance should be added to the 503A bulks list; the committee’s recommendation is non-binding but is generally treated as the central public-record analysis of the nomination.

What’s at stake

A favorable recommendation would clear the path for traditional 503A compounders to prepare Epitalon for individual patient prescriptions. An unfavorable recommendation would leave the substance ineligible for routine compounding under 503A, with continued enforcement discretion against bulk-substance use outside FDA-approved drug products. Because indexed peer-reviewed human-trial data on Epitalon are limited, FDA’s briefing document and the PCAC discussion are likely to be the most consolidated public regulatory analysis of the molecule available to date. This page will be updated when those briefing materials are released.